TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium (Caputo et al 2008; Schroeder et al 2008; Yang et al 2008). It is now clinically established that promoting anion secretion in the airway leads to enhanced mucus clearance and reduced exacerbation frequency in CF patients and as such TMEM16A represents an important target for the next generation of mucokinetics. Importantly, positive regulators of TMEM16A function will be expected to be of benefit in all CF patients, irrespective of their CFTR mutational status.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by RocheOctober 7, 2020 - 7:02 am
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002August 17, 2020 - 9:00 am
- Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical OfficerFebruary 10, 2020 - 9:00 am
- Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patientsJanuary 8, 2020 - 10:16 am
Follow Us On Twitter
Just a week to go until the premier of 'The Magic Line' virtual campaign video, raising awareness and donations to speed breakthroughs and cures for the 10% of the #CysticFibrosis community without targeted therapies: https://rb.gy/cbhaiw